Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Accounting for future costs in medical cost-effectiveness analysis.

D Meltzer1

  • 1University of Chicago and National Bureau of Economic Research, IL 60637, USA. dmeltzer@medicine.bsd.uchicago.edu

Journal of Health Economics
|January 7, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Wildfire disruptions and cancer care: A multi-institutional study of radiotherapy treatment adherence in Northern California.

The journal of climate change and health·2026
Same author

Clinical predictors of donor antibody titre and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial.

Journal of internal medicine·2020
Same author

Impact of patient decision aids on appropriate and timely access to hip or knee arthroplasty for osteoarthritis: a randomized controlled trial.

Osteoarthritis and cartilage·2015
Same author

Ambiguous stimuli and delayed matching to sample.

Behavioural processes·2014
Same author

Intradimensional and extradimensional shifts in conditional discrimination.

Behavioural processes·2014
Same author

A trial of inpatient indication based prescribing during computerized order entry with medications commonly used off-label.

Applied clinical informatics·2013
Same journal

Competition matters: Uniform vs. indication-based pricing of pharmaceuticals.

Journal of health economics·2026
Same journal

Integrating equity and productivity in health evaluation.

Journal of health economics·2026
Same journal

Income and immunity: The consequences of social security administration reform for childhood infection risk.

Journal of health economics·2026
Same journal

When fewer children mean shorter lives: Fertility policy and elderly well-being in China.

Journal of health economics·2026
Same journal

Health dynamics and reporting bias at retirement: An analysis using high-frequency data.

Journal of health economics·2026
Same journal

Intertemporal coordination in volunteer markets.

Journal of health economics·2026
See all related articles

Most cost-effectiveness analyses overlook crucial future expenses, leading to inaccurate health intervention assessments. Including all lifetime costs ensures accurate analysis, especially for interventions impacting longevity over quality of life.

Area of Science:

  • Health Economics
  • Medical Decision Making
  • Biostatistics

Background:

  • Current cost-effectiveness analyses (CEA) often limit future cost considerations to related illnesses.
  • This limited scope is a point of ongoing debate within health economics.

Purpose of the Study:

  • To demonstrate that consistent cost-effectiveness analysis requires incorporating all future medical and non-medical expenditures for lifetime utility maximization.
  • To evaluate the impact of including all future costs on the assessment of medical interventions.

Main Methods:

  • Theoretical economic modeling to align CEA with lifetime utility maximization principles.
  • Quantitative estimation of future medical and non-medical costs associated with health interventions.

Related Experiment Videos

Main Results:

  • Cost-effectiveness analysis aligns with lifetime utility maximization only when all future medical and non-medical expenditures are included.
  • Including all future costs can significantly change the absolute and relative cost-effectiveness of interventions.
  • Current methods may overstate the cost-effectiveness of life-extending interventions compared to quality-of-life improving ones, particularly in older populations.

Conclusions:

  • A comprehensive inclusion of all future costs is essential for accurate cost-effectiveness analysis.
  • The findings have significant implications for healthcare policy and resource allocation, especially concerning interventions for aging populations.
  • Revising current CEA methodologies to incorporate lifetime expenditures is recommended for more reliable health economic evaluations.